CHDI
Isis Pharmaceuticals initiates clinical study of ISIS-HTTRx in patients with Huntington’s disease
First therapy designed to directly target the cause of disease Isis earns $22 million milestone payment from Roche Carlsbad, Calif., July 21, 2015 –Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced ...Read More
New assay measures pathogenic protein in Huntington’s disease patients’ spinal fluid
A new assay has been able to measure for the first time the build-up of a harmful mutant protein in the nervous system of patients during the progression of Huntington’s disease (HD). Published today in the Journal of Clinical Investigation, ...Read More
GNS Healthcare and CHDI Foundation collaborate to identify novel drug targets for Huntington’s disease
CAMBRIDGE, Mass. and NEW YORK CITY – Nov. 12, 2014 – GNS Healthcare (GNS), a leading provider of big data analytics in health care, announced today that CHDI Foundation, Inc. (CHD ...Read More
10th Annual CHDI HD Therapeutics Conference – Registration Now Closed!
The 10th Annual HD Therapeutics Conference will be held February 23-26, 2015, at the Parker Hotel in Palm Springs, California. You can reg ...Read More
Charles River’s Early Drug Discovery Business and CHDI Foundation Extend Huntington’s Disease Collaboration
WILMINGTON, Mass. – Nov. 5, 2014 -- Charles River Laboratories International, Inc. announced today that CHDI Foundation, Inc. has extended its ongoing collaboration for an additional five years through to 2019. The collaboration, which began in 200 ...Read More
Evotec and CHDI Foundation extend ongoing collaboration to fight Huntington’s disease
Hamburg, Germany – 11 September 2014: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that CHDI Foundation, Inc. (“CHDI”) has extended and restated its collaboration with Evotec through 2017. The col ...Read More
Structural Genomics Consortium and CHDI Foundation announce open-access collaboration to discover new drug targets for Huntington’s disease
Toronto, Canada & New York City, USA; June 4, 2014 - The Structural Genomics Consortium (SGC) and CHDI Foundation have entered into a unique open-access research collaboration to discover and characterize new drug targets for Hunt ...Read More
Discovery research and systems biology leader joins CHDI
New York, June 2 2014: CHDI has appointed Thomas F Vogt, PhD as its new Vice President of Discovery and Systems Biology. Vogt and his group will work closely with the translational biology, chemistry, and clinical groups at CHDI to identify an ...Read More
KineMed and CHDI Foundation Extend Huntington’s Disease Collaboration
EMERYVILLE, Calif., May 19, 2014 -- KineMed, Inc. ( ...Read More